Understanding dynamic immune–tumor interactions is essential for improving cancer detection, monitoring treatment response, and identifying early signs of relapse. However, current immune monitoring strategies in oncology rely heavily on venous blood sampling, limiting longitudinal resolution and increasing cost and patient burden. Molecular profiling approaches such as RNA sequencing provide deep biological insight but are not traditionally compatible with frequent, remote sampling. HemoPrint addresses this limitation by enabling scalable, decentralized immune transcriptomic profiling using dried blood microsamples.
Traditional blood collection for whole blood gene expression profiling and biomarker analysis often requires a visit to a healthcare professional, posing challenges for special populations (sick, fragile health, immobile), or for large-scale studies requiring repeated sampling. Blood microsampling, the process of obtaining small volumes of capillary blood, holds great promise to overcome these challenges. We have developed a cost-effective, high-throughput platform for processing self-collected blood microsamples using Mitra Volumetric Adsorptive Microsampling (VAMS) devices for downstream RNA sequencing.